| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
The contribution of inflammation (arthritis) to the quality of sleep and vise versa was studied in the patients with rheumatoid arthritis (RA). We have studied 517 patients with rheumatoid arthritis with biologic DMARDs (tocilizmab 175, abatacept 98, or infliximab 144). Evaluation was made with Pittsburgh score, Epworth score and actigraphy, and the results were compared with arthritic indices. As a result, Pittsburgh score showed presence of sleep disturbance, in which global score showed 6.42±2.76 which was higher than normal level 5, thus indicating the presence of sleep disturbance. Actigraphy showed that %sleep 89.1±10.5, total wake after sleep 49.5±45.2 min, average wake after sleep onset 9.9±23.3times, and these values were abnormal as compared with healthy controls. Further, these values showed a posistive correlation with C-reactive protein levels and swollen joint counts of patients. After biologic DMARDs treatments (n=517), these abnormalities were all normalized.
|
